QUANTUM BIOPHARMA-B SUB VOT
QNTMNASDAQTrading Snapshot
- Day Range
- $2.36 – $2.50
- 52-Week Range
- $2.85 – $23.10
- Volume (shares)
- 14,946.746
- Avg Volume (shares)
- —
- Shares Outstanding
- 8.2M
- Next Earnings
- 2026-11-06
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 167.1x
- EPS (TTM)
- $-5.70
- Dividend Yield
- —
- Dilution (1yr)
- +278.4%
QUANTUM BIOPHARMA-B SUB VOT
QNTM
StockOtter · stockotter.spaceAbout QUANTUM BIOPHARMA-B SUB VOT
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and
Thermo Fisher Scientific (NYSE:TMO) Sets New 52-Week High – Time to Buy?
Thermo Fisher Scientific Inc. (NYSE: TMO - Get Free Report)'s stock price hit a new 52-week high on Tuesday. The company traded as high as $694.33 and last traded at $678.8880, with a volume of 218570 shares. The stock h
Quantum BioPharma Signs Contract with Thermo Fisher Scientific's Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy Strategic collaboration with leading glo
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
AUSTIN, Texas, Sept. 30, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the l
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.
Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.